These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9883501)

  • 1. [Prevention in the 21st century. Athero-thrombosis and ischemic events].
    Z Kardiol; 1998 Nov; 87(11 Suppl Atherothro):1-3. PubMed ID: 9883501
    [No Abstract]   [Full Text] [Related]  

  • 2. [Myocardial infarct, stroke and vascular events reduced by a third].
    Z Kardiol; 1997 Nov; 86(11 Suppl Myokardinf):1-3. PubMed ID: 9437253
    [No Abstract]   [Full Text] [Related]  

  • 3. Patients with peripheral arterial disease in the CHARISMA trial.
    Cacoub PP; Bhatt DL; Steg PG; Topol EJ; Creager MA;
    Eur Heart J; 2009 Jan; 30(2):192-201. PubMed ID: 19136484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming aspirin resistance: increased platelet inhibition with combination aspirin and clopidogrel and high dose aspirin therapy in aspirin resistant patients with peripheral vascular disease.
    Wong S; Morel-Kopp MC; Chen Q; Appleberg M; Ward CM; Lewis DR
    Thromb Haemost; 2006 Jun; 95(6):1042-3. PubMed ID: 16732389
    [No Abstract]   [Full Text] [Related]  

  • 5. [New analysis of CAPRIE (Clopidogrel vs Aspirin in Patients at Risk of Ischemic Events) shows: myocardial infarct most effectively prevented in the clopidogrel group].
    Z Kardiol; 1998 Feb; 87(2 Suppl Herzinfark):1-4. PubMed ID: 9541675
    [No Abstract]   [Full Text] [Related]  

  • 6. Withdrawal of clopidogrel in active gastric bleeding.
    Mourad JJ
    Ann Intern Med; 2010 May; 152(10):685; author reply 685. PubMed ID: 20479035
    [No Abstract]   [Full Text] [Related]  

  • 7. [Clopidogrel and aspirin versus aspirin alone in prevention of atherothrombotic events. The results of CHARISMA study].
    Gaciong Z
    Kardiol Pol; 2006 May; 64(5):548-51; discussion 551-2. PubMed ID: 16752345
    [No Abstract]   [Full Text] [Related]  

  • 8. Combination antiplatelet agents in ischemic cerebrovascular disease.
    Moussouttas M; Papamitsakis N
    Mt Sinai J Med; 2005 Jan; 72(1):16-22. PubMed ID: 15682258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lower aspirin doses in dual antiplatelet therapy optimise efficacy and safety: CHARISMA follow-up study.
    Cardiovasc J Afr; 2009; 20(3):205. PubMed ID: 19575092
    [No Abstract]   [Full Text] [Related]  

  • 10. Extracardiac vascular disease and effectiveness of sustained clopidogrel treatment.
    Mukherjee D; Topol EJ; Moliterno DJ; Brennan DM; Ziada K; Cho L; Steinhubl SR;
    Heart; 2006 Jan; 92(1):49-51. PubMed ID: 15845611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.
    Wang TH; Bhatt DL; Fox KA; Steinhubl SR; Brennan DM; Hacke W; Mak KH; Pearson TA; Boden WE; Steg PG; Flather MD; Montalescot G; Topol EJ;
    Eur Heart J; 2007 Sep; 28(18):2200-7. PubMed ID: 17673448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.
    Bhatt DL; Flather MD; Hacke W; Berger PB; Black HR; Boden WE; Cacoub P; Cohen EA; Creager MA; Easton JD; Hamm CW; Hankey GJ; Johnston SC; Mak KH; Mas JL; Montalescot G; Pearson TA; Steg PG; Steinhubl SR; Weber MA; Fabry-Ribaudo L; Hu T; Topol EJ; Fox KA;
    J Am Coll Cardiol; 2007 May; 49(19):1982-8. PubMed ID: 17498584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An aspirin a day: are we barking up the wrong willow tree?
    Krantz MJ; Berger JS; Hiatt WR
    Pharmacotherapy; 2010 Feb; 30(2):115-8. PubMed ID: 20099985
    [No Abstract]   [Full Text] [Related]  

  • 14. Diabetes mellitus and peripheral vascular disease: is aspirin effective in preventing vascular events?
    Cimminiello C; Milani M
    Diabetologia; 1996 Nov; 39(11):1402-4. PubMed ID: 8933012
    [No Abstract]   [Full Text] [Related]  

  • 15. [Resistance to desaggregants: causes, clinical implication, methods of diagnosis and correction].
    Kremneva LV; Shalaev SV
    Ter Arkh; 2008; 80(12):89-95. PubMed ID: 19227916
    [No Abstract]   [Full Text] [Related]  

  • 16. Chronic antithrombotic therapy in post-myocardial infarction patients.
    Nagarakanti R; Sodhi S; Lee R; Ezekowitz M
    Cardiol Clin; 2008 May; 26(2):277-88, vii. PubMed ID: 18407000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current status of primary and secondary prevention of cerebral apoplexy].
    Zippel C
    Wien Med Wochenschr; 1995; 145(19-20):537-41. PubMed ID: 8571596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspirin combined with clopidogrel (Plavix) decreases cardiovascular events in patients with acute coronary syndrome.
    Walker CW; Dawley CA; Fletcher SF
    Am Fam Physician; 2007 Dec; 76(11):1643-5. PubMed ID: 18092705
    [No Abstract]   [Full Text] [Related]  

  • 19. Consensus on anti-platelet therapy in peripheral arterial disease: saving lives and limbs.
    Donnelly R; Collinson DJ
    Platelets; 2003; 14(7-8):403-6. PubMed ID: 14713508
    [No Abstract]   [Full Text] [Related]  

  • 20. [Cardiovascular secondary prevention. Convincing results with Clopidogrel].
    Z Kardiol; 1998 Jul; 87(7 Suppl Uberzeugen):1-4. PubMed ID: 9722966
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.